Roflumilast Cream (Zoryve) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1711b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Aminopyridines, Phosphodiesterase 4 Inhibitors, Cyclopropanes. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa), which can be used in patients ≥3 months old, was the first.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Roflumilast Cream (Zoryve) for Atopic Dermatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1711b
Vancouver
Roflumilast Cream (Zoryve) for Atopic Dermatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1711b
BibTeX
@article{euvimed2024,
title = {Roflumilast Cream (Zoryve) for Atopic Dermatitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1711b}
}
EUVIMED